|
[1]National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018update[J].J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957．
|
|
[2]DIEHL AM,DAY C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J].N Engl J Med,2017,377(21):2063-2072．
|
|
[3]MASARONE M,FEDERICO A,ABENAVOLI L,et al.Non alcoholic fatty liver:Epidemiology and natural history[J].Rev Recent Clin Trials,2014,9(3):126-133．
|
|
[4]SHU JR,LI JQ,LIU Q.Analysis of epidemiology and risk factors of nonalcoholic fatty liver disease[J].J Clin Hepatol,2019,35(9):2085-2090.(in Chinese)舒筠然，李俊琪，刘琼．非酒精性脂肪性肝病的流行病学和危险因素分析[J]．临床肝胆病杂志，2019,35(9):2085-2090．
|
|
[5]ZHANG Y,WANG H,ZHANG L,et al.Codonopsis lanceolata polysaccharide CLPS alleviates high fat/high sucrose diet-induced insulin resistance via anti-oxidative stress[J].Int J Biol Macromol,2020,145:944-949．
|
|
[6]GÓMEZ-ZORITA S,MILTON-LASKIBAR I,AGUIRRE L,et al.Effects of pterostilbene on diabetes,liver steatosis and serum lipids[J].Curr Med Chem,2019.[Online ahead of print]
|
|
[7]YANG SZ,XU SX,DONG L,et al.Ganshuang granules alleviates non-alcoholic steatohepatitis in rats[J].J Shanxi Med Univ,2016,47(3):205-210.(in Chinese)杨素贞，许绍娴，董蕾，等．肝爽颗粒对大鼠非酒精性脂肪性肝炎的治疗作用[J]．山西医科大学学报，2016,47(3):205-210．
|
|
[8]SUN HQ,WANG XQ,SHI HB,et al.Ganshuang granules protect mouse liver from chronic injury induced by CCl4via autophagy[J].Chin J Clin Hepatol,2015,31(7):1114-1119.(in Chinese)孙海青，王小琪，时红波，等．肝爽颗粒对CCl4诱导的慢性肝损伤小鼠模型和肝损伤细胞模型的保护作用[J]．临床肝胆病杂志，2015,31(7):1114-1119．
|
|
[9]KANG WW,ZHOU L,DANG SS,et al.Multi center clinical study on the treatment of chronic hepatitis B with Ganshuang Granules[J].China J Tradit Chin Med Pharma,2017,32(12):5689-5693.(in Chinese)康玮玮，周莉，党双锁，等．肝爽颗粒治疗慢性乙型肝炎的多中心临床研究[J]．中华中医药杂志，2017,32(12):5689-5693．
|
|
[10]WEI SN,SU XY,XU GH.Anomaly of triglyceride metabolism in liver lead to NAFLD[J].Chin J Biochem Mol Biol,2016,32(2):123-132.(in Chinese)魏苏宁，苏雪莹，徐国恒．肝细胞甘油三酯代谢途径异常与脂肪肝[J]．中国生物化学与分子生物学报，2016,32(2):123-132．
|
|
[11]SHI H,SHI H,REN F,et al.Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti-fibrosis effect by inhibition of mammalian target of rapamycin[J].J Cell Mol Med,2017,21(3):500-509．
|
|
[12]BYRNE CD,TARGHER G.NAFLD:A multisystem disease[J].JHepatol,2015,62(1 Suppl):s47-s64．
|
|
[13]COBBINA E,AKHLAGHI F.Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J].Drug Metab Rev,2017,49(2):197-211．
|
|
[14]SANYAL AJ.Past,present and future perspectives in nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol,2019,16(6):377-386．
|
|
[15]ASGHARPOUR A,CAZANAVE SC,PACANA T,et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol,2016,65(3):579-588．
|
|
[16]WU Q,LIU J,LIU LJ,et al.Establishment of an ex Vivo model of nonalcoholic fatty liver disease using a tissue-engineered liver[J].ACS Biomater-Sci Eng,2018,4(8):3016-3026．
|
|
[17]DONNELLY KL,SMITH CI,SCHWARZENBERG SJ,et al.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease[J].J Clin Invest,2005,115(5):1343-1351．
|
|
[18]KOO SH.Nonalcoholic fatty liver disease:Molecular mechanisms for the hepatic steatosis[J].Clin Mol Hepatol,2013,19(3):210-215．
|
|
[19]HAN WJ,LIU S,DUAN ZP,et al.Molecular mechanism of hepatocyte steatosis in non-alcoholic fatty liver disease[J].Chin J Gastroenterol Hepotol,2018,27(10):1103-1109.(in Chinese)韩伟佳，刘霜，段钟平，等．非酒精性脂肪性肝病中肝细胞脂肪变性分子机制的研究[J]．胃肠病学和肝病学杂志，2018,27(10):1103-1109．
|
|
[20]di PIETRO SM,SANTOMEJA.Structural and biochemical characterization of the lungfish(Lepidosiren paradoxa)liver basic fatty acid binding protein[J].Arch Biochem Biophys,2001,388(1):81-90．
|
|
[21]MAO J,DEMAYO FJ,LI H,et al.Liver-specific deletion of acetyl-Co A carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis[J].Proc Natl Acad Sci U S A,2006,103(22):8552-8557．
|
|
[22]DORN C,RIENER MO,KIROVSKI G,et al.Expression of fatty acid synthase in nonalcoholic fatty liver disease[J].Int J Clin Exp Pathol,2010,3(5):505-514．
|
|
[23]AVRAMOGLU RK,BASCIANO H,ADELI K.Lipid and lipoprotein dysregulation in insulin resistant states[J].Clin Chim Acta,2006,368(1-2):1-19．
|
|
[24]KOTZKA J,MULLER-WIELAND D.Sterol regulatory elementbinding protein(SREBP)-1:Gene regulatory target for insulin resistance?[J].Expert Opin Ther Targets,2004,8(2):141-149．
|
|
[25]DUVNJAK M,LEROTIC'I,BARSIC'N,et al.Pathogenesis and management issues for non-alcoholic fatty liver disease[J].World J Gastroenterol,2007,13(34):4539-4550.
|
DownLoad: